A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)
Study of Drug (XmAb20717) in Subjects with Advanced Solid Tumors (DUET-2) - Melanoma, Breast Cancer, Lung Cancer, Stomach Cancer
Sponsor: Xencor, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR8229
U.S. Govt. ID: NCT03517488
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This research study will learn more about the drug, XmAb20717. XmAb20717 is designed to activate your own cells to kill your tumor. The primary purposes of this research study are to: determine the safety and tolerability of XmAb20717, see if XmAb20717 works in treating specific tumors , learn about the side effects from XmAb20717. Cancers include: Melanoma, Breast Cancer, Lung Cancer, Stomach Cancer
This study is closed
Investigator
Mark Stein, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have any of the following solid tumors? Melanoma, Breast, Lung, or Stomach Cancer? Yes No
Have you had treatment for your cancer before and progressed? Or, are there no standard therapies for your cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE